Monsanto Growth Ventures’ first investment portfolio shows its strategic focus areas

Monsanto Growth Ventures (MGV) announced its first investment portfolio on January 6, 2016. MGV, the venture capital arm of Monsanto, has committed to significant relationships with several companies over the last three years. Steve Padgette, VP of research and development (R&D) strategy, said th...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email Thank you!

Related Research

Bowery's $300 million Series C raises no doubt for the growth of controlled-environment agriculture (CEA)

News Commentary | May 27, 2021

Led by Fidelity Management & Research, the round included existing investors GV, General Catalyst, GGV Capital, Temasek, and Groupe Artémis and new investors Amplo and Gaingels, among others. According to the press release, this round is the largest private fundraise to date for an indoor ... To read more, click here.

Apeel raises $250 million Series E, bringing its valuation to more than $2 billion

News Commentary | August 19, 2021

Led by Temasek, this Series E funding round also had other prominent investors and brings Apeel's total funding to $635 million. This latest investment will allow Apeel to expand its supply chain reach and develop its recent technology acquisition based on hyperspectral imaging. Apeel's glycerolipid... Not part of subscription

Nature-inspired herbicide discovery startup FortePhest raises undisclosed Series B funds

News Commentary | February 15, 2022

Israeli biotech startup FortePhest will use funds from a round led by BASF Venture Capital and Orbia Ventures to accelerate pipeline development to meet regulatory requirements and commercialize products. FortePhest is developing several herbicides using a noncoded amino acid, meta‑tyrosine. This ... Not part of subscription